The Inflation Reduction Act (IRA) temporarily extended Affordable Care Act premium subsidies and instituted an insulin co-pay cap for Medicare beneficiaries, but bipartisan agreement is needed to make these changes permanent and more broadly applicable, explained A. Mark Fendrick, MD.
The Inflation Reduction Act (IRA) temporarily extended Affordable Care Act (ACA) premium subsidies and instituted an insulin co-pay cap for Medicare beneficiaries, but bipartisan agreement is needed to make these changes permanent and more broadly applicable, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the Center for Value-Based Insurance Design at the University of Michigan.
Transcript
The IRA extended ACA premium subsidies another 3 years. Do you think subsidies may continue to be extended?
Well, you'd like to think that making insurance coverage more affordable would be popular and not partisan. But unfortunately, just about everything in the United States—from baseball to space exploration—has turned out to be partisan, in addition to health care. So, while it's certainly better than not extending these subsidies, to extend them for 3 years, it wouldn't surprise me to have this issue come to fore quite quickly, and it wouldn't surprise most of the listeners to understand that one party will support strengthening the Affordable Care Act and continuing its legacy and others may not be as interested.
The IRA was a pared-down version of the Build Back Better Act, which had several proposals to reform the ACA. Do you see a future life for any of those that did not make it into the IRA?
One of the more important proposals, and one that fell just 3 Republican senators’ votes short, was the application of an insulin co-pay cap of $35 a month in the commercial marketplace. We're very pleased and excited to know that this same policy was passed as part of the Medicare program. So now, people who require insulin will not have to pay exorbitant amounts of money out of pocket to get this potentially lifesaving drug.
It has been stated by Majority Leader [Chuck] Schumer [D-New York] that there will be a return to vote on the insulin co-pay cap in the commercial marketplace after the midterm elections. And I'm hopeful that Congress will act prudently and wisely and pass this extremely important policy that will impact people to use a potentially lifesaving drug for which, in my opinion, there is really no overuse.
Contributor: Breaking the Cycle—RSAT Program Improving Reentry in Arizona
March 15th 2024Arizona is well suited to benefit from its 1115 demonstration waiver requested from CMS because it already has a robust justice-involved reentry initiative called the Residential Substance Abuse Treatment (RSAT) Program, which is emerging as an archetype of successful reentry programs that can serve as a template for other states to emulate.
Read More
Evolution of HDHPs With VBID Components Can Improve Care for Chronic Disease
March 14th 2024Over the course of the last 20 years, high-deductible health plans (HDHPs) have undergone an evolution. Today’s plans, with more high-value services covered predeductible, can improve care for people with chronic diseases, said panelists at the 2024 Value-Based Insurance Design (V-BID) Summit.
Read More
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More